medigraphic.com
ISSN 0210-5187 (Electronic)

2004, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2004; 32 (3)

Skin Features of the Polycystic Ovary Syndrome. Physiopathology, Diagnosis and Management

Carvalho LJ A, Carvalho LA

Language: Portugués
References: 67
Page: 93-99
PDF size: 177.47 Kb.


Text Extraction

This article is a review that introduce to the dermatologists the Polycystic Ovary Syndrome (PCOS), and its physiopathology, as a disease of interest for this medical specialty. The paper also presents the hormonal influences, primary the androgen hormones, and its actions on skin, sebaceous gland and hair follicles that induce the presentation of skin features as greasy skin, acne, hirsutism, androgenetic alopecia and Acanthosis nigricans. Statistically the presence of Hirsutism in PCOS women occurs in 70% of the patients, greasy skin and acne in 30-40% and androgenetic alopecia (8%) and Acanthosis nigricans (5%) in a lower incidence. The article also describe the anatomy and physiopathology of each of these skin features and the laboratory findings, including the ones related with the hormonal disturbances, that can help the dermatologist and the general physician reach the PCOS diagnosis. There are topical, systemic and cosmetic therapeutical purposes that contribute to improve away the skin signs of the PCOS and that correct the basal physiopathologic metabolism of the PCOS patients.


REFERENCES

  1. Lobo R, Carmina E. The Importance of Diagnosing the Polycystic Ovary Syndrome. Ann Intern Med 2000; 132: 989-93.

  2. Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in Adolescent Girls with Polycystic Ovary Syndrome. Arch Pediatr Adolesc Med 2002; 156: 556-60.

  3. Taylor AE. Insulin-Lowering Medications in Polycystic Ovary Syndrome. Obstet Gynecol Clin 2000; 27: 583-95.

  4. Baillargeon JP, Iuorno MJ, Nestler JE, et al. Insulin Sensitizers for Polycystic Ovary Syndrome. Clin Obstet Gynaecol 2003; 46:325-40.

  5. Meirelles RMR. Desvendando os Mistérios da Mulher (pelo Menos os Endócrinos). Arq Bras Endocrinol Metab 2001; 45:317-9.

  6. Tartagni M, Schonauer LM, De Salvia MA, et al. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2000; 73: 718-23.

  7. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. Survey of the Polycystic Ovary Syndrome in the Greek Island of Lesbos: Hormonal and Metabolic Profile. J Clin Endocrinol Metab 1999; 84: 4006-11.

  8. Kovacs GT. Polycystic Ovary Syndrome. Cambridge University Press, 2000,UK.

  9. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003; 18: 598-603.

  10. Shaw JC. Hormonal therapy in Dermatology. Dermatol Clin 2001; 19: 169-78.

  11. Meisler JG. Toward Optimal Health: The Experts Discuss Facial Skin and Related Concerns in Women. J Women Health 2003; 12: 533-9.

  12. Sttaford DEJ, Gordon CM. Adolescents androgen abnormalities. Curr Opin Obstet Gynecol 2002; 14: 445-51.

  13. Pastor CL, Griffin-Korf ML, Aloi JA, et al. Polycystic Ovary Syndrome: Evidence for Reduced Sensitivity of the Gonadotropin-Releasing Hormone Pulse Generator to Inhibition by Estradiol and Progesterone. J Clin Endocrinol Metab 1998; 83: 251-62.

  14. Lobo RA. Role of the adrenal in polycystic ovary syndrome. Semin Reprod Endocrinol 1984; 2: 251-62.

  15. De Leo V, La Marca A, Petraglia F. Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome. Endocr Rev 2003; 24: 633-67.

  16. Nelson VL, Qin K, Rosenfield RL, et al. The Biochemical Basis for Increased Testosterone Production in Theca Cells Propagated from Patients with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2001; 86: 5925-33.

  17. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61.

  18. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol 2002; 147: 717-25.

  19. Jayagopal V, Kilpatrick ES, Holding S, et al. The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome. J Clin Endocrinol Metab 2002; 87: 1560-2.

  20. Harris GS, Kozarich JW. Steroid 5α-reductase inhibitors in androgen-dependent disorders. Curr Opin Chem Biol 1997; 1:254-9.

  21. Springer K, Brown M, Stulberg DL. Common Hair Disorders. Am Fam Physician 2003; 68:107-8.

  22. Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis. Endocr Rev 1997; 18: 774-800.

  23. Hachanefioglu B, Mamhmutoglu I, Sercelik A, et al. Hyperandrogenism: Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 526-8.

  24. Nacul A, Comim F, Spritzel PM. Aspectos Neuroendócrinos na Síndrome dos Ovários Policísticos. Arq Bras Endocrinol Metab 2003; 47: 432-9.

  25. Norman RJ, Wu R, Stankiewicz MT. Polycystic Ovary Syndrome. MJA 2004; 180: 132-7.

  26. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol 1989; 31: 87-120.

  27. Yen SSC. The Polycystic Ovary syndrome. Clin Endocrinol (Oxf) 1980; 12: 177-207.

  28. Doldi N, Marsiglio E, Destefani A, et al. Polycystic ovary syndrome: anomalies in progesterone Production. Human Reprod 1998; 13: 290-3.

  29. Mitwally MF, Casper RF. Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr Opin Obstet Gynecol 2002; 14: 255-63.

  30. Gordon CM. Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome. Pediatr Clin North Am 1999; 46: 519-43.

  31. Fassnatch, Martin, et al. Beyond Adrenal and Ovarian Androgen Generation: Increased Peripheral 5alpha-Reductase Activity in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2003; 88: 2760-6.

  32. Sir-Petermann T, Angel B, Maliqueo M, et al. Prevalence of type II Diabetes mellitus and Insulin Resistance in parents of women with Polycystic Ovary Syndrome. Diabetol 2002; 45: 459-64.

  33. Rittmaster RS, Deshwal N, Lehman L, et al. The Role of Adrenal Hyperandrogenism, Insulin Resistance, and Obesity in the Pathogenesis of Polycystic Ovarian Syndrome. J Clin Endocrinol Metab 1993; 76: 1295-1300.

  34. Patel K, Coffler MS, Dahan MH, et al. Increased Luteinizing Hormone Secretion in Women with Polycystic Ovary Syndrome Is Unaltered by Prolonged Insulin Infusion. J Clin Endocrinol Metab 2003; 88:5456-1.

  35. Hogeveen KN, Cousin P, Pugeat M, et al. Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. J Clin Investigation 2002; 109: 973-81.

  36. Krentz, Andrew J, Insulin Resistance A Clinical Handbook. Blackwell Science 2002, Oxford, UK.

  37. Fitzpatrick TB, Johnson RA, Wolff K. Color Atlas and Synopsis of Clinical Dermatology - Common and Serious Diseases. 1997, 3rd Edition, McGraw-Hill, US.

  38. Garafalo L, Boscozzi AM, Mastrandea V, Bonifazi E. Acantosis nigricans vulgare: un indicatori di iperinsulinemia. Eur J Pediat Dermatol 2000; 13: 85-8.

  39. Franks, Stephen, et al. Nutrition, insulin and Polycystic Ovary Syndrome. Rev Reproduction 1996; 1: 47-53.

  40. Poy M, Wiltgen D, Spritzer PM, Perfil Hormonal e Metabólico em Pacientes Hirsutas com a Síndrome dos Ovários Policísticos. Arq Bras Endocrinol Metab 2001; 45: 352-60.

  41. Ralf P, Cotsarelis G. The biology of Hair Follicles. N England J Medicine 1999; 341:491-7.

  42. Azziz R. The Evaluation and Management of Hirsutism. Obstet Gynecol 2003; 101: 995-1007.

  43. Ferriman D, Gallwey JD. Clinical Assessment of body hair growth in women. J Clin Endocrinol Metabol 1961; 21: 1440-7.

  44. Hunter MH, Carek PJ. Evaluation and Treatment of Women with Hirsutism Am Fam Phycisian 2003; 67: 2565-72.

  45. Bershad SV. The Modern Age of Acne Therapy: A Review of Current Treatment Options. Mount Sinai J Medicine 2001; 68: 279-286.

  46. Faure M. Acné et hormones. Rev Prat 2002; 52: 850-3.

  47. Tan JKL, Vasey K, Fung KY. Attitudes of female Patients regarding Oral Contraceptives for Acne Treatment. J Cutan Med Surg 2001: 471-4.

  48. Seaman HE, Vries CS, Farmer RDT. Differences in the use of combined oral contraceptives amongst women with and without acne. Hum Reprod 2003; 18: 515-21.

  49. Krowchuk DP. Treating Acne. Med Clin North Am - Adolescent medicine 2000; 8:811-24.

  50. Wolf Jr JE. Maintenance Therapy for Acne Vulgaris: The Fine Balance Between Efficacy, Cutaneous Tolerability, and Adherence. SKINmed 2004, 3: 23-6.

  51. Ludwig E. Classification of the types of androgenetic alopecia occuring in the female sex. Br J Dermatol 1977; 97: 247-54.

  52. Price V. Treating Hair Loss. N England J Medicine 1999; 341: 964-73.

  53. Bonet Serra B, Sanchéz-Vera I, Cocho Gómez P, et al. Alteraciones relacionadas com el síndrome X y bajos níveles de vitamina E en niños con obesidad y acantosis nigricans. An Pediatr (Barc) 2004; 60: 142-7.

  54. Spritzer, Poli Mara, Revisitando o Hirsutismo. Arq Bras Endocrinol Metab 2002; 46: 127-36.

  55. Marx Theresa L, Mehta, Adi E. Polycystic ovary syndrome: Pathogenesis and treatmentover the short and long term. Cleveland Clin J Med 2003; 70: 31-45.

  56. Barbieri RL: The role of adipose tissue and hyperinsulinemia in the development of hyperandrogenism in women. In L’Hermite ML (ed): Progress in Reproductive Biology and Medicine 1990. Basel, Switzerland, Karger.

  57. Ducluzeau PH, Cousin P, Malvoisin E, et al. Glucose-to-Insulin Ratio Rather than Sex Hormone-Binding Globulin and Adiponectin Levels Is the Best Predictor of Insulin Resistance in Nonobese Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2003; 88: 3626-31.

  58. Legro R, Finegood D, Dunaif A. A Fasting Glucose to Insulin Ratio Is a Useful Measure of Insulin Sensitivity in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 1998; 83: 2694-8.

  59. Valmore Bermúdez P, et al. Homeostasis Model Assessment (HOMA) en Pacientes Diabéticos Tipo 2. Med Intern (Caracas) 2000; 16.

  60. Rajkhowa M, Neary RH, Kumpatla P, et al. Altered Composition of High Density Lipoproteins in Women with the Polycystic Ovary Syndrome. J Clin Endocrinol Metab 1997; 82: 3389-94.

  61. Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol 2001; 54: 447-53.

  62. Healy E, Simpson N. Fortnightly Review Acne vulgaris. Br Med J 1994; 308: 831-3.

  63. Bunliffe B. Diseases of the skin and their tratment - Acne. The Pharmaceutical J 2001; 267: 749-52.

  64. Goldberg DJ. Laser hair Removal. Dermatol Clin 2002; 20: 561-7.

  65. Limmer BL. The density issue in hair transplantation. Dermatol Surg 1997; 23:747-50.

  66. Unger WP, David LM. Laser hair transplantation. J Dermatol Surg Oncol 1994; 20: 515-21.

  67. Avram M. Hair transplantation in women. Seminar Cutan Med Surg 1998; 18: 172-6.




2020     |     www.medigraphic.com